CONTEXT: The receptor activator of nuclear factor kappaB ligand (RANKL) is essential for osteoclast and, possibly, osteoblast activation and may represent a key link between bone formation and resorption. OBJECTIVE: To determine the relationship between serum level of RANKL and the risk of nontraumatic fracture. DESIGN, SETTING, AND PARTICIPANTS: As part of a prospective population-based study conducted in Bruneck, Italy, we recorded all fractures that occurred between 1990 and 2000 in 906 participants and classified them as traumatic (n = 115) or nontraumatic (n = 31). Serum levels of RANKL and osteoprotegerin and characteristics of bone metabolism and lifestyle were assessed in 1990 and at follow-up in 1995 and 2000. MAIN OUTCOME MEASURE: Incident nontraumatic fracture by levels of RANKL. RESULTS: Levels of RANKL did not differ between sexes and were not related to age, menopausal status, lifestyle characteristics, or data from bone ultrasound at the heel. However, RANKL emerged as a significant predictor of nontraumatic fracture. In pooled logistic regression analysis, the relative risks of nontraumatic fracture in the lowest and middle vs highest tertile for RANKL were 10.0 (95% confidence interval [CI], 2.3-43.1) and 3.9 (95% CI, 0.8-19.0) (P<.001 for trend), respectively. Patients in the highest-tertile group had a low risk of fracture even in the presence of other predisposing factors, whereas women aged 60 years or older in the lowest tertile had a 5-year rate of nontraumatic fracture greater than 7%. CONCLUSIONS: A low level of RANKL is an independent predictor of nontraumatic fracture. This finding is consistent with the hypothesis of an important role of RANKL in human bone turnover and if confirmed in future investigations may gain relevance for assessment of fracture risk.
CONTEXT: The receptor activator of nuclear factor kappaB ligand (RANKL) is essential for osteoclast and, possibly, osteoblast activation and may represent a key link between bone formation and resorption. OBJECTIVE: To determine the relationship between serum level of RANKL and the risk of nontraumatic fracture. DESIGN, SETTING, AND PARTICIPANTS: As part of a prospective population-based study conducted in Bruneck, Italy, we recorded all fractures that occurred between 1990 and 2000 in 906 participants and classified them as traumatic (n = 115) or nontraumatic (n = 31). Serum levels of RANKL and osteoprotegerin and characteristics of bone metabolism and lifestyle were assessed in 1990 and at follow-up in 1995 and 2000. MAIN OUTCOME MEASURE: Incident nontraumatic fracture by levels of RANKL. RESULTS: Levels of RANKL did not differ between sexes and were not related to age, menopausal status, lifestyle characteristics, or data from bone ultrasound at the heel. However, RANKL emerged as a significant predictor of nontraumatic fracture. In pooled logistic regression analysis, the relative risks of nontraumatic fracture in the lowest and middle vs highest tertile for RANKL were 10.0 (95% confidence interval [CI], 2.3-43.1) and 3.9 (95% CI, 0.8-19.0) (P<.001 for trend), respectively. Patients in the highest-tertile group had a low risk of fracture even in the presence of other predisposing factors, whereas women aged 60 years or older in the lowest tertile had a 5-year rate of nontraumatic fracture greater than 7%. CONCLUSIONS: A low level of RANKL is an independent predictor of nontraumatic fracture. This finding is consistent with the hypothesis of an important role of RANKL in human bone turnover and if confirmed in future investigations may gain relevance for assessment of fracture risk.
Authors: C M Bastos; I M Araújo; M H Nogueira-Barbosa; C E G Salmon; F J A de Paula; L E A Troncon Journal: Osteoporos Int Date: 2017-04-12 Impact factor: 4.507
Authors: Lidan You; Sara Temiyasathit; Peling Lee; Chi Hyun Kim; Padmaja Tummala; Wei Yao; Wade Kingery; Amanda M Malone; Ronald Y Kwon; Christopher R Jacobs Journal: Bone Date: 2007-09-26 Impact factor: 4.398
Authors: Pedro Mezquita-Raya; Magdalena de la Higuera; Diego Fernández García; Guillermo Alonso; María Estrella Ruiz-Requena; Juan de Dios Luna; Fernando Escobar-Jiménez; Manuel Muñoz-Torres Journal: Osteoporos Int Date: 2005-02-12 Impact factor: 4.507
Authors: Danja Sarink; Helena Schock; Theron Johnson; Kim Overvad; Marianne Holm; Anne Tjønneland; Marie-Christine Boutron-Ruault; Mathilde His; Marina Kvaskoff; Heiner Boeing; Pagona Lagiou; Eleni-Maria Papatesta; Antonia Trichopoulou; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Carlotta Sacerdote; H B As Bueno-de-Mesquita; Carla H van Gils; Petra H Peeters; Elisabete Weiderpass; Antonio Agudo; Maria-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; Kay Tee Khaw; Ruth Travis; Laure Dossus; Mark Gunter; Sabina Rinaldi; Melissa Merritt; Elio Riboli; Rudolf Kaaks; Renée T Fortner Journal: Cancer Prev Res (Phila) Date: 2017-07-12
Authors: Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan Journal: Arterioscler Thromb Vasc Biol Date: 2010-05-06 Impact factor: 8.311
Authors: Adetunji T Toriola; Catherine M Appleton; Xiaoyu Zong; Jingqin Luo; Katherine Weilbaecher; Rulla M Tamimi; Graham A Colditz Journal: Cancer Prev Res (Phila) Date: 2018-10-23